---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-004570"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-04-02T23:59:59+00:00"
generated_at: "2026-06-04T03:40:08.021498+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NRx Pharma 2023 net loss $30.2M; expects top-line data this month for NRX-101 TRBD trial

## Summary
- Net loss for full-year 2023: $30.2M vs $39.8M in 2022; Q4 2023 loss $4.3M vs $10.2M in Q4 2022.
- Cash $4.6M at Dec 31, 2023; added $8M in Q1 2024 via equity sales and $5.1M milestone from Alvogen/Lotus.
- Expects top-line data in April 2024 from Phase 2b/3 trial of NRX-101 in TRBD; achieved 94% rater concordance.
- Plans to spin out HOPE Therapeutics for IV Ketamine; NDA filing expected by June 2024; term sheets for $60M investment.
- Reduced G&A expenses 50% YoY to $14.2M in 2023 from $27.3M; corporate overhead decreased by half.

## SEC filing metadata
- accession: 0001558370-24-004570
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-04-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000155837024004570/0001558370-24-004570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000155837024004570/nrxp-20240401x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-004570
- JSON: https://secwatch.observer/filing/0001558370-24-004570.json
- Plain text: https://secwatch.observer/filing/0001558370-24-004570.txt

## Key facts
- Earnings Releases
  NRX Pharmaceuticals, Inc. reported financial results for the fourth fiscal quarter and year ending December 31, 2023.
  - Period: the fourth fiscal quarter and year ending December 31, 2023
  - Result: reported results
  source text: On April 1, 2024, NRx Pharmaceuticals, Inc. issued a press release announcing its financial results for the fourth fiscal quarter and year ending December 31, 2023 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000155837024004570/0001558370-24-004570-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.